 concurrent
anticoagulants, and infusion techniques. Streptokinase, although rarely used due to the risks of allergic reactions and
bleeding, remains the only thrombolytic agent approved by
the United States Food and Drug Administration for the
treatment of DVT. Several series, however, have reported
the successful use of urokinase,16,69-72 tissue plasminogen
activator,69-71 rete